Research program stimulates and supports basic, translational, and clinical research on the various manifestations of tuberous sclerosis complex (tsc) to further the development of clinical therapies and, ultimately, a cure for tsc. Directed by steven l. Roberds, phd, chief scientific officer, the tsc alliance research program builds and fosters collaborations between basic and clinical researcher… Read more
Research program stimulates and supports basic, translational, and clinical research on the various manifestations of tuberous sclerosis complex (tsc) to further the development of clinical therapies and, ultimately, a cure for tsc. Directed by steven l. Roberds, phd, chief scientific officer, the tsc alliance research program builds and fosters collaborations between basic and clinical researchers by collecting and distributing tsc natural history data and biosamples, through collaborative preclinical and clinical research programs, and by hosting biennial international tsc research conferences.since 1984, the tsc alliance has invested more than $44 million into tsc research projects through grants and contracts: $21.6 Million in research grants and postdoctoral fellowships, $6.2 million into the natural history database and biosample repository, $14.3 million into the preclinical consortium, and $2.3 million into the clinical research consortium and clinical research network. Grant and fellowship applications are reviewed in a three-step process: (1) All applications are reviewed by a committee comprised of scientists knowledgeable about the topic area for scientific merit and of caregivers or adults affected by tsc for potential impact on the lives of those affected by tsc; (2) The science and medical committee of the board of directors evaluates the grant review committee's recommendations and the relevance of the applications to the tsc alliance's funding priorities; and (3) The board of directors then reviews the recommendations of the science and medical committee and makes final approval for funding. For a complete list of currently funded projects and an archive of past awardees, please visit tscalliance.org/researchers/grants-funding/.implemented in 2006, the tsc natural history database (nhd) captures clinical data to document the impact of the disease on a person's health over his/her lifetime. The database serves as a resource of information that helps tsc researchers better understand the progression of the disease, design hypothesis-driven questions to hasten the discovery of new treatments and identify persons with tsc who are eligible to participate in research studies. As of December 2025, the natural history database contained 2,932 participants enrolled in the project from among 24 tsc clinic sites and through the tsc alliance. The tsc alliance provides funding to participating clinics to perform data entry, monitors the integrity of the database, and makes data available to investigators to answer specific research questions and identify potential participants for clinical trials and studies building upon the natural history database, the tsc biosample repository is a tsc alliance-directed project initiated in 2014 that will impact research for decades to come. The tsc alliance's science and medical committee identified this as a gap that can only be filled effectively with leadership of the tsc alliance, guided by a steering committee of clinicians, researchers and community members. High-quality biosamples such as blood, dna, and tissues linked to detailed clinical data are critical for researchers to understand why tsc is so different from person to person. Samples in the repository are linked to detailed clinical data in our existing tsc natural history database and are available to qualified researchers worldwide. Samples are housed at and distributed from the van andel institute in grand rapids, mi, under control of the tsc alliance. As of December 2025, the biosample repository has acquired 3,117 blood, buccal (cheek) swab, or tissue samples. Since inception, 4,036 portions of samples have been distributed to 57 distinct researchers for 63 distinct projects.the organization continues to grow the biosample repository by collecting blood samples annually from participants who volunteer to do so, enabling researchers to study changes in proteins and other molecules in the blood over time; adding additional tsc clinics as participating biosample repository collection sites; and collecting blood using mobile phlebotomy, enabling people to donate samples regardless of where they live in the us and whether they are seen at a tsc clinic. Since the inception of our mobile phlebotomy initiative, we have acquired 635 blood samples via mobile phlebotomy. To encourage and enable more researchers to utilize biosamples, the tsc alliance awarded three seed grants in 2025, totaling $57,952.64, to labs that submitted meritorious and innovative ideas for research on tsc biosamples.the tsc alliance's whole-genome sequencing (wgs) initiative using dna from blood samples in our biosample repository has sequenced 242 samples since inception, with an additional 48 samples in process. This initiative supports clinical validation of variants found via wgs in either the tsc1 or tsc2 gene, and genetic results are offered back to participants along with a genetic counseling session free of charge to the family to help them better understand their unique tsc diagnosis and provide valuable information for future decision making such as family planning.in December 2021, the tsc alliance added the tsc self-report portal to the tsc natural history database. This portal permits the collection of patient-reported outcomes on how tsc affects individuals and families, which will complement medical data in the natural history database. The purpose of this initiative is to help the tsc alliance and tsc researchers better understand the perspective of those affected by tsc to develop tools to measure improvement in areas most important to the tsc community. Eventually, these measurements can be used to identify endpoints for clinical trials and evidence-based guidelines for treatment.one of the most impactful aspects of tsc on the quality of life for people living with tsc is tsc-associated neuropsychiatric disorders (tand). Therefore, the tsc alliance's first use of the portal is through collaboration with the tandem project (empowering families through technology: A mobile-health project to reduce the tand identification and treatment gap) by allowing the community to complete the self-quantified tand checklist (tand-sq). At the end of 2025, 114 individuals had completed the tand-sq through the self-report portal.the tsc alliance launched the tsc preclinical consortium in 2015 to help advance more drug candidates into clinical testing. To achieve this end, the preclinical consortium provides the infrastructure to foster collaboration between academia and pharmaceutical industry researchers and for access to resources designed to help facilitate drug development in tsc. Collaborating with the tsc community, the consortium has identified and implemented robust and reproducible cell and animal models for tsc manifestations including tumors, epilepsy, and tand. In 2022, the tsc alliance entered into a partnership with the lam foundation to add lam mouse models to the preclinical consortium. The tsc alliance has licenses to use specific tsc mouse models for experiments carried out by the preclinical consortium, and all mouse license agreements include the rights for the tsc alliance to perform experiments under contract for commercial entities. This ensures data generated by the preclinical consortium can be used to accelerate the development of new treatments by commercial entities as well as academic investigators. Experiments are executed at partnering research institutions to ensure consistency in testing, data acquisition and interpretation. Epilepsy studies are conducted at psychogenics (us), and the tumor graft model and cell-based assays are conducted at porsolt (france). The van andel research institute, a non-profit research organization, maintains a colony of tsc2+/- aj mice and f l7-cre-tsc2 mice on behalf of the preclinical consortium. The preclinical consortium invites compound nominations from academic and industry researchers to continue to refresh our pipeline based on the latest data and novel ideas. The nominations are peer reviewed by consortium members and prioritized by the preclinical consortium steering committee for funding by the tsc alliance. If the tsc alliance funds the study, the data are shared with the consortium for transparency and stimulation of additional hypotheses. A members meeting is held annually to keep members engaged and aligned on the consortium's strategy and priorities. Partnership with pharmaceutical companies is an important aspect of the consortium, as these organizations have the infrastructure to efficiently move preclinical research findings to clinical testing and eventually commercial distribution. The preclinical consortium ended 2025 with 12 active industry partners, increasing the total number to 31 industry partners since 2016.